This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 290035 results found since Jan 2013.

Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy
AbstractRipretinib (Qinlock®) is a small molecule inhibitor of the receptor tyrosine kinases KIT and platelet-derived growth factor receptor α (PDGFRA) and is approved for the treatment of gastrointestinal stromal tumours as a fourth-line of therapy. After successive cycles of treatment, gastrointestinal stromal tumours can carry a wide array of mutations, which makes resistance to treatment more likely. Ripretinib has a dual mechanism of action that allows it to target a broad spectrum of mutations in KIT or PDGFRA. The pivotal phase III INVICTUS trial demonstrated an increase of progression-free survival in patients re...
Source: Drugs - October 25, 2022 Category: Drugs & Pharmacology Source Type: research

Perforation as a rare presentation of gastric gastrointestinal stromal tumours: a case report and review of the literature.
CONCLUSIONS: We present the first English report of a perforated gastric GIST. More common presentations include abdominal pain and gastrointestinal bleeding. Although rare, GISTs should be considered in the differential diagnoses of perforated gastrointestinal masses. PMID: 24417854 [PubMed - in process]
Source: Annals of the Royal College of Surgeons of England - January 1, 2014 Category: Surgery Authors: Skipworth J, Fanshawe A, West M, Al-Bahrani A Tags: Ann R Coll Surg Engl Source Type: research

Laparoscopic resection of large gastric gastrointestinal stromal tumours.
CONCLUSIONS: Laparoscopic procedures can be successfully performed during management of large gastric GISTs, bigger than 4 cm, and should be considered for all non-metastatic cases. The appropriate approach can be determined by assessing the anatomical location of each tumour. PMID: 28133498 [PubMed - in process]
Source: Videosurgery and Other Miniinvasive Techniques - February 1, 2017 Category: Surgery Tags: Wideochir Inne Tech Maloinwazyjne Source Type: research

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours, Published online: 22 February 2019; doi:10.1038/s41416-019-0389-6Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
Source: British Journal of Cancer - February 22, 2019 Category: Cancer & Oncology Authors: C ésar Serrano Adri án Mariño-Enríquez Derrick L. Tao Julia Ketzer Grant Eilers Meijun Zhu Channing Yu Aristotle M. Mannan Brian P. Rubin George D. Demetri Chandrajit P. Raut Ajia Presnell Arin McKinley Michael C. Heinrich Jeffrey T. Czaplinski Ewa Si Source Type: research

Gastrointestinal stromal tumours and other primary gastrointestinal neoplasms. A single-center experience.
CONCLUSION: Patients with GIST run the risk of developing a second neoplasm, nearly twice as high as the general population with a negative impact on survival; also, incidental GIST is often observed requiring a better molecular characterization for the high risk of developing second neoplasms with the aim of achieving an early diagnosis. KEY WORDS: Gist, Second neoplasm, Surgery. PMID: 33554950 [PubMed - in process]
Source: Annali Italiani di Chirurgia - February 9, 2021 Category: Surgery Tags: Ann Ital Chir Source Type: research

Primary cilia in Gastric Gastrointestinal Stromal Tumours (GISTs): an ultrastructural study.
In this study, we report for the first time the presence of primary cilia (PCs) in spindle and epithelioid tumour cells, an ultrastructural feature we consider of special interest that has hitherto been ignored in the literature dealing with the ultrastructure of GISTs. We also point out the frequent occurrence of multivesicular bodies (MVBs). The ultrastructural findings described in gastric GISTs in this study appear to be relevant considering the critical roles played by PCs and MVBs recently demonstrated in tumourigenic processes. PMID: 23672577 [PubMed - as supplied by publisher]
Source: J Cell Mol Med - May 15, 2013 Category: Molecular Biology Authors: Castiella T, Muñoz G, Luesma MJ, Santander S, Soriano M, Junquera C Tags: J Cell Mol Med Source Type: research

Presentation and management of gastrointestinal stromal tumours.
This study highlights the changing presentation and treatment approach, as well as the excellent outcomes achievable for GIST tumours. PMID: 23909154 [PubMed - in process]
Source: Ir Med J - June 1, 2013 Category: Journals (General) Authors: Mongan AM, Malik V, Rowley S, Claxton Z, Muldoon C, O'Toole D, Ravi N, Reynolds JV Tags: Ir Med J Source Type: research

Surgical Management of Gastric Gastrointestinal Stromal Tumours: Comparison of Outcomes for Local and Radical Resection.
Authors: Madhavan A, Phillips AW, Donohoe CL, Willows RJ, Immanuel A, Verril M, Griffin SM Abstract Gastrointestinal stromal tumours (GISTs) most commonly originate from the stomach. Their treatment is dependent on size and whether they are symptomatic. Curative treatment requires surgery, which may be preceded by neoadjuvant imatinib if it is felt that this will aid in achieving clear (R0) resection margins. The aim of this study was to evaluate outcomes from patients that underwent a "local" organ-preserving operation, with those that required a more radical resection, and the influences on selecting a more radic...
Source: Gastroenterology Research and Practice - July 25, 2018 Category: Gastroenterology Tags: Gastroenterol Res Pract Source Type: research

Cancers, Vol. 15, Pages 2875: Measuring Tumour Imatinib Concentrations in Gastrointestinal Stromal Tumours: Relevant or Redundant?
M. E. Desar Imatinib plasma trough concentrations are associated with efficacy for patients treated for advanced or metastatic KIT-positive gastrointestinal stromal tumours (GISTs). This relationship has not been studied for patients treated in the neoadjuvant setting, let alone its correlation with tumour drug concentrations. In this exploratory study we aimed to determine the correlation between plasma and tumour imatinib concentrations in the neoadjuvant setting, investigate tumour imatinib distribution patterns within GISTs, and analyse its correlation with pathological response. Imatinib concentrations were measur...
Source: Cancers - May 23, 2023 Category: Cancer & Oncology Authors: Eline L. Giraud Loek A. W. de Jong Erik van den Hombergh Suzanne E. J. Kaal Nielka P. van Erp Ingrid M. E. Desar Tags: Article Source Type: research

The expression of hematopoietic progenitor cell antigen CD34 is regulated by DNA methylation in a site ‐dependent manner in gastrointestinal stromal tumours (GISTs)
This study aimed at understanding the regulation of CD34 in GISTs and clarification of its site‐dependent expression. Two sample sets of primary GISTs were interrogated including 52 fresh‐frozen and 134 paraffin‐embedded and formalin‐fixed specimens. DNA methylation analysis was performed by HumanMethylation450 BeadChip array in three cell lines derived from gastric and intestinal GISTs, and differentially methylated CpG sites were established upstream of CD34. The methylation degree was further quantified by pyrosequencing and inversely correlated with CD34 mRNA and protein abundance. The gene's expression could b...
Source: International Journal of Cancer - July 26, 2017 Category: Cancer & Oncology Authors: Irina Bure, Alexander Braun, Claudia Kayser, Helene Geddert, Inga ‐Marie Schaefer, Silke Cameron, Michael B. Ghadimi, Phillip Ströbel, Martin Werner, Arndt Hartmann, Stefan Wiemann, Abbas Agaimy, Florian Haller, Evgeny A. Moskalev Tags: Research Article Source Type: research

Current knowledge of gastrointestinal stromal tumours
Abstract Gastrointestinal stromal tumours, the most common mesenchymal tumours of the gastrointestinal tract, are immunohistochemically and ultrastructurally different from other mesenchymal tumours. They can occur anywhere in the GI tract, the commonest site being the stomach. GIST occurrence is not restricted to the bowel but can also involve unusual sites. The diagnosis and treatment of GIST have been revolutionized over the past decade. The mainstay of treatment remains surgical resection with adequate margins. Though these tumours are refractory to conventional chemotherapy or radiotherapy, they show a good ...
Source: Hellenic Journal of Surgery - September 1, 2014 Category: Surgery Source Type: research

Clinical Insights Into Gastrointestinal Stromal Tumours Clinical Insights Into Gastrointestinal Stromal Tumours
This study examined the treatment outcomes of GISTs, highlighting some of the diagnostic and therapeutic challenges.Frontline Gastroenterology
Source: Medscape Today Headlines - February 13, 2017 Category: Consumer Health News Tags: Radiology Journal Article Source Type: news

Prognostic role of the primary tumour site in patients with operable small intestine and gastrointestinal stromal tumours: a large population-based analysis.
Authors: Ye H, Xin H, Zheng Q, Shen Q, Dai W, Wu F, Zheng C, Chen P Abstract The postoperative recurrence risk of gastrointestinal stromal tumour (GIST) should be estimated when considering adjuvant systemic therapy. Previous studies in the literature have suggested that small intestinal GISTs are more aggressive than gastric GISTs. We assessed the prognostic role of the primary tumour site in patients with operable GIST to compare the outcomes of gastric and small intestinal GISTs over a decade of treatment. The Surveillance, Epidemiology, and End Results (SEER) database was queried for cases of gastric and small ...
Source: Oncotarget - March 2, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST).
Conclusion: In advanced GIST patients treated with sunitinib, older and low-weight patients are at risk for grade 3 and 4 toxicity. Clinical (prior imatinib use and metastases), biological (neutrophil and platelet count) and treatment characteristics independently predict PFS and OS. PMID: 31345082 [PubMed - as supplied by publisher]
Source: Acta Oncologica - July 25, 2019 Category: Cancer & Oncology Authors: Den Hollander D, Van der Graaf WTA, Desar IME, Le Cesne A Tags: Acta Oncol Source Type: research

Bromodomain and extraterminal domain inhibitor enhances the antitumor effect of imatinib in gastrointestinal stromal tumours.
Abstract In gastrointestinal stromal tumours (GISTs), the function of bromodomain-containing 4 (BRD4) remains underexplored. BRD4 mRNA abundance was quantified in GISTs. In the current study, we investigated the role of BRD4 in GISTs. Our results show a significant enhancement in BRD4 mRNA and a shift from very low-risk/low-risk to high-risk levels as per NCCN specifications. Overexpression of BRD4 correlated with unfavourable genotype, nongastric location, enhanced risk and decreased disease-free survival, which were predicted independently. Knockout of BRD4 in vitro suppressed KIT expression, which led to inacti...
Source: J Cell Mol Med - January 18, 2020 Category: Molecular Biology Authors: Mu J, Sun P, Ma Z, Sun P Tags: J Cell Mol Med Source Type: research